Andrew Nash, Ph.D. is the Chief Scientific Officer of CSL Limited, a leading global biotechnology company with a portfolio of life-saving medicines and vaccines. Andrew has extensive research experience in the areas of immunology and cytokine biology. He leads a large team focused on the discovery and development of new recombinant antibody and protein-based medicines to treat serious human diseases. He has extensive experience in the pharmaceutical / biotechnology sector, including at the CEO level. Dr. Nash completed his Ph.D. in Immunology at the University of Melbourne.